Immunocellular Thera (IMUC) 0.54 $IMUC
Hot Stock: ImmunoCellular Therapeutics, Shares Drop 12.9% (IMUC)
Comtex SmarTrend(R) - Thu Feb 12, 10:39AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 12.9% to $0.58 on 6.7x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.8 million shares, vs. average volume of 270,000 shares per day. The stock has underperformed the Dow (-12.9% to the Dow's 0.3%) and underperformed the S&P 500 (-12.9% to the S&P's 0.6%) during today's trading.
IMUC: 0.54 (-0.03)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants
PR Newswire - Thu Feb 12, 7:06AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at a price to the public of $0.60 per share, and warrants to purchase up to an aggregate of 18,655,000 shares of its common stock. The net offering proceeds to ImmunoCellular from this offering are expected to be approximately $14.6 million, after deducting the underwriting discount and estimated offering expenses payable by ImmunoCellular, but excluding the exercise of any warrants.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015
PR Newswire - Wed Jan 28, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.
IMUC: 0.54 (-0.03)
What's To Like About CytRx's Brain Cancer Data?
Investing Healthcare - at Seeking Alpha - Tue Jan 20, 2:37AM CST
CYTR: 2.96 (+0.23), IMUC: 0.54 (-0.03)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), HPTX: 26.83 (-0.05)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 165.94 (+0.03), NWBO: 6.07 (+0.13), MRK: 58.81 (-0.07), IMUC: 0.54 (-0.03)
Stock to Watch: ImmunoCellular Therapeutics Up 13.7% (IMUC)
Comtex SmarTrend(R) - Mon Dec 29, 12:39PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 13.7% to $0.76 on 1.0x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 675,000 shares, vs. average volume of 653,000 shares per day. The stock has outperformed the Dow (13.7% to the Dow's -0.0%) and outperformed the S&P 500 (13.7% to the S&P's 0.2%) during today's trading.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
PR Newswire - Wed Dec 17, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens that are commonly expressed on glioblastoma. The claims of US Patent No. 8,871,211, which issued October 28, 2014, include methods of treating neural cancer by administering a dendritic cell composition comprising peptide epitopes of the six tumor antigens of ICT-107. The claims specifically cover administration of the recited dendritic cell composition to a patient suffering from glioma, which is inclusive of glioblastoma multiforme.
IMUC: 0.54 (-0.03)
Stock to Watch: ImmunoCellular Therapeutics Down 7.2% (IMUC)
Comtex SmarTrend(R) - Thu Dec 04, 12:41PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 7.2% to $0.93 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 480,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's 0.0%) and underperformed the S&P 500 (-7.2% to the S&P's 0.0%) during today's trading.
IMUC: 0.54 (-0.03)
Can The Uptrend Continue for ImmunoCellular (IMUC)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 8:36AM CST
Can The Uptrend Continue for ImmunoCellular (IMUC)?
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics (IMUC) Soars: Stock Rises 40.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 7:51AM CST
ImmunoCellular Therapeutics, Ltd. (IMUC) was a big mover last session, as its shares rose almost 41% on the day.
ANIP: 62.69 (-0.43), ILMN: 198.54 (+1.81), IMUC: 0.54 (-0.03), AFFX: 11.45 (+0.02)
Hot Stock: ImmunoCellular Therapeutics, Shares Gain 8.8% (IMUC)
Comtex SmarTrend(R) - Mon Dec 01, 10:10AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 8.8% to $0.65 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 471,000 shares, vs. average volume of 436,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's -0.4%) and outperformed the S&P 500 (8.8% to the S&P's -0.9%) during today's trading.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from European Medicines Agency on Advancing ICT-107 to Phase III Program
PR Newswire - Mon Dec 01, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM). The EMA guidance is consistent with the positive feedback the Company received from the US FDA relative to the scope, design and endpoints of the program and the inclusion of patients based on HLA and MGMT status. ImmunoCellular intends to finalize the design of the phase III program, ensuring harmony between US and EU trial protocols, with the goal of being in position to initiate the phase III program. The Company now is evaluating options for funding the phase III program, which may enable the initiation in 2015.
IMUC: 0.54 (-0.03)
Hot Stock: ImmunoCellular Therapeutics, Shares Drop 6.2% (IMUC)
Comtex SmarTrend(R) - Mon Nov 17, 12:04PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 6.2% to $0.61 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 417,000 shares, vs. average volume of 386,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.1%) and underperformed the S&P 500 (-6.2% to the S&P's -0.2%) during today's trading.
IMUC: 0.54 (-0.03)
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 13.0% (IMUC)
Comtex SmarTrend(R) - Fri Nov 14, 10:08AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 13.0% to $0.65 on 2.0x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 739,000 shares, vs. average volume of 368,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's -0.0%) and outperformed the S&P 500 (13.5% to the S&P's 0.1%) during today's trading.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014
PR Newswire - Fri Nov 14, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT:IMUC) announces the presentation today of updated efficacy data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, being held in Miami, FL. Patrick Y. Wen, MD, Director of the Center for Neuro-Oncology at Dana Farber Cancer Institute and Professor of Neurology at Harvard Medical School, and principal investigator on the trial, will present the maturing data set in patients with newly diagnosed glioblastoma multiforme (GBM) in an oral presentation.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics beats by $0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:02AM CST
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Announces Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" (NYSE MKT: IMUC) today announced financial results for the quarter ended September 30, 2014.
IMUC: 0.54 (-0.03)
Investors look to Lighten Up on Shares of ImmunoCellular Therapeutics, Shares Down 5.1% (IMUC)
Comtex SmarTrend(R) - Fri Nov 07, 10:37AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 5.1% to $0.59 on 1.4x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 459,000 shares, vs. average volume of 323,000 shares per day. The stock has underperformed the Dow (-5.0% to the Dow's 0.0%) and underperformed the S&P 500 (-5.0% to the S&P's 0.1%) during today's trading.
IMUC: 0.54 (-0.03)
Hot Stock: ImmunoCellular Therapeutics, Shares Drop 12.9% (IMUC)
Comtex SmarTrend(R) - Thu Feb 12, 10:39AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 12.9% to $0.58 on 6.7x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 1.8 million shares, vs. average volume of 270,000 shares per day. The stock has underperformed the Dow (-12.9% to the Dow's 0.3%) and underperformed the S&P 500 (-12.9% to the S&P's 0.6%) during today's trading.
IMUC: 0.54 (-0.03)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants
PR Newswire - Thu Feb 12, 7:06AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at a price to the public of $0.60 per share, and warrants to purchase up to an aggregate of 18,655,000 shares of its common stock. The net offering proceeds to ImmunoCellular from this offering are expected to be approximately $14.6 million, after deducting the underwriting discount and estimated offering expenses payable by ImmunoCellular, but excluding the exercise of any warrants. IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015
PR Newswire - Wed Jan 28, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 2:00 pm ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City. IMUC: 0.54 (-0.03)
What's To Like About CytRx's Brain Cancer Data?
Investing Healthcare - at Seeking Alpha - Tue Jan 20, 2:37AM CST
CYTR: 2.96 (+0.23), IMUC: 0.54 (-0.03)
Global Peptide Vaccine Market & Pipeline Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/6qv33n/global_peptide) has announced the addition of the "Global Peptide Vaccine Market & Pipeline Insight" report to their offering. Various peptide vaccines available in market have been made by using different methods of recombinant DNA technology. Subunit vaccines group seems to occupy large market in coming years due to their versatile nature and ease of development. Large scale manufacturing if also easy with minimal number steps that helps in decreasing time, reduce wastage of raw materials and have high cost-arbitrage. Over time, reduced marketing time coupled with their therapeutic property will make them highly suitable candidate with optimistic growth potential. Peptide vaccines for treatment and prevention of cancer are expected to occupy a major share in global vaccine market as well as in other fields like infectious and neurobiological disease. It is expected that investigators would be able to extend the indications for the peptide vaccines in near future that would be instrumental in widespread penetration of peptide vaccines. Immunotoxicity, clinical/ preclinical requirements and regulatory issues are realistic hurdles which may limit the market penetration of peptide vaccines at global level. Many peptide vaccines have successfully made niche in global market which gives an idea about optimistic future that would be achieved in coming years. Global Peptide Vaccine Market & Pipeline Insight Report Highlights: - Peptide Vaccine Pipeline in Clinical Pipeline: 69 - Majority of Peptide Vaccine in Preclinical Phase: 19 - Competitive Landscape & Patent Analysis Key Topics Covered: 1. Introduction to Peptide Vaccine 2. Mechanism of Peptide Vaccine 3. Global Peptide Vaccine Market Overview 4. Global Peptide Vaccine Market Dynamics 5. Global Peptide Vaccine Market Future Prospects 6. Global Peptide Vaccine Pipeline by Phase, Indication, Company & Country 7. Discontinued & No Development Reported in Peptide Vaccine Clinical Pipeline 8. Competitive Landscape - Apitope Technology - BiondVax Pharmaceuticals - Circassia - Eli Lily - Galena Biopharmaceuticals - GlaxoSmithKline - Hyperion Therapeutics - ImmunoCellular Therapeutics - Merck - OncoTherapy Science For more information visit http://www.researchandmarkets.com/research/6q...al_peptide
MRK: 58.81 (-0.07), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), HPTX: 26.83 (-0.05)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 165.94 (+0.03), NWBO: 6.07 (+0.13), MRK: 58.81 (-0.07), IMUC: 0.54 (-0.03)
Stock to Watch: ImmunoCellular Therapeutics Up 13.7% (IMUC)
Comtex SmarTrend(R) - Mon Dec 29, 12:39PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 13.7% to $0.76 on 1.0x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 675,000 shares, vs. average volume of 653,000 shares per day. The stock has outperformed the Dow (13.7% to the Dow's -0.0%) and outperformed the S&P 500 (13.7% to the S&P's 0.2%) during today's trading.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
PR Newswire - Wed Dec 17, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens that are commonly expressed on glioblastoma. The claims of US Patent No. 8,871,211, which issued October 28, 2014, include methods of treating neural cancer by administering a dendritic cell composition comprising peptide epitopes of the six tumor antigens of ICT-107. The claims specifically cover administration of the recited dendritic cell composition to a patient suffering from glioma, which is inclusive of glioblastoma multiforme. IMUC: 0.54 (-0.03)
Stock to Watch: ImmunoCellular Therapeutics Down 7.2% (IMUC)
Comtex SmarTrend(R) - Thu Dec 04, 12:41PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 7.2% to $0.93 on 1.1x average daily volume. ImmunoCellular Therapeutics has traded 480,000 shares thus far today, vs. average volume of 457,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's 0.0%) and underperformed the S&P 500 (-7.2% to the S&P's 0.0%) during today's trading.
IMUC: 0.54 (-0.03)
Can The Uptrend Continue for ImmunoCellular (IMUC)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 8:36AM CST
Can The Uptrend Continue for ImmunoCellular (IMUC)?
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics (IMUC) Soars: Stock Rises 40.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 7:51AM CST
ImmunoCellular Therapeutics, Ltd. (IMUC) was a big mover last session, as its shares rose almost 41% on the day.
ANIP: 62.69 (-0.43), ILMN: 198.54 (+1.81), IMUC: 0.54 (-0.03), AFFX: 11.45 (+0.02)
Hot Stock: ImmunoCellular Therapeutics, Shares Gain 8.8% (IMUC)
Comtex SmarTrend(R) - Mon Dec 01, 10:10AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 8.8% to $0.65 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 471,000 shares, vs. average volume of 436,000 shares per day. The stock has outperformed the Dow (8.8% to the Dow's -0.4%) and outperformed the S&P 500 (8.8% to the S&P's -0.9%) during today's trading.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from European Medicines Agency on Advancing ICT-107 to Phase III Program
PR Newswire - Mon Dec 01, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM). The EMA guidance is consistent with the positive feedback the Company received from the US FDA relative to the scope, design and endpoints of the program and the inclusion of patients based on HLA and MGMT status. ImmunoCellular intends to finalize the design of the phase III program, ensuring harmony between US and EU trial protocols, with the goal of being in position to initiate the phase III program. The Company now is evaluating options for funding the phase III program, which may enable the initiation in 2015. IMUC: 0.54 (-0.03)
Hot Stock: ImmunoCellular Therapeutics, Shares Drop 6.2% (IMUC)
Comtex SmarTrend(R) - Mon Nov 17, 12:04PM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 6.2% to $0.61 on 1.1x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 417,000 shares, vs. average volume of 386,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.1%) and underperformed the S&P 500 (-6.2% to the S&P's -0.2%) during today's trading.
IMUC: 0.54 (-0.03)
Traders Get Bullish on Shares of ImmunoCellular Therapeutics, Shares Up 13.0% (IMUC)
Comtex SmarTrend(R) - Fri Nov 14, 10:08AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's best performing penny stocks, up 13.0% to $0.65 on 2.0x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 739,000 shares, vs. average volume of 368,000 shares per day. The stock has outperformed the Dow (13.5% to the Dow's -0.0%) and outperformed the S&P 500 (13.5% to the S&P's 0.1%) during today's trading.
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014
PR Newswire - Fri Nov 14, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT:IMUC) announces the presentation today of updated efficacy data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, being held in Miami, FL. Patrick Y. Wen, MD, Director of the Center for Neuro-Oncology at Dana Farber Cancer Institute and Professor of Neurology at Harvard Medical School, and principal investigator on the trial, will present the maturing data set in patients with newly diagnosed glioblastoma multiforme (GBM) in an oral presentation. IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics beats by $0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:02AM CST
IMUC: 0.54 (-0.03)
ImmunoCellular Therapeutics Announces Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular"
(NYSE MKT: IMUC) today announced financial results for the quarter ended September 30, 2014. IMUC: 0.54 (-0.03)
Investors look to Lighten Up on Shares of ImmunoCellular Therapeutics, Shares Down 5.1% (IMUC)
Comtex SmarTrend(R) - Fri Nov 07, 10:37AM CST
ImmunoCellular Therapeutics (NASDAQ:IMUC) is one of today's worst performing penny stocks, down 5.1% to $0.59 on 1.4x average daily volume. Thus far today, ImmunoCellular Therapeutics has traded 459,000 shares, vs. average volume of 323,000 shares per day. The stock has underperformed the Dow (-5.0% to the Dow's 0.0%) and underperformed the S&P 500 (-5.0% to the S&P's 0.1%) during today's trading.
IMUC: 0.54 (-0.03)
